Malignant Ascites – Optional Management using Hyperthermic Peroperative Chemotherapy (HIPEC)
Authors:
F. Antoš; P. Dytrych; P. Vítek *; O. Ryska; J. Marvan; Z. Šerclová
Authors‘ workplace:
Chirurgická klinika 1. LF UK a IPVZ FN Praha Bulovka, přednosta: prof. MUDr. František Antoš, CSc.
; Ústav radiační onkologie 1. LF a IPVZ FN Praha Bulovka, přednosta: prof. MUDr. Luboš Petruželka
*
Published in:
Rozhl. Chir., 2010, roč. 89, č. 4, s. 237-241.
Category:
Monothematic special - Original
Overview
146 procedures using hyperthermic intraoperative peritoneal chemotherapy (HIPEC) were performed in 121 patients in the FNB Surgical Clinic, during 2000–2008. During these procedures, ascites was detected in 30 subjects (24.8%) and its volume was 250–11,000 ml. The patients concerned could not undergo radical surgery for their GIT or gynecological tumors. The patient group was divided into two subgroups. Subgroup A (22 subjects) included subjects, in whom at least palliative debulking of the tumors (usually total omentectomy) was feasible, and the procedure was followed by HIPEC. Subgroup B (8 patients) included subjects who could not undergo even the minimum debulking procedure because of extensive tumorous spread in their abdominal cavity, underwent only HIPEC. Out of the total of 22 subjects in Subgroup A, ascites was not postoperatively recorded in 17 patients. In 5 patients, ascites was gradually formed from month 6.3 onwards, however, it only reached subclinical levels. In this subgroup, 7 patients exited (at the mean postoperative month 11.7), the remaining 15 patients were surviving at that time, out of whom 9 patients were surviving for more than 1 year after the procedure, 4 subjects were surviving for over 2 years after the procedure and 2 patients for over 4 years. The geometric mean survival time 16.49 months, standard deviation of 1.57. In Subgroup B (8 patients), no ascites was detected in 3 subjects until their death (37.5%), further 5 subjects presented with ascites at the mean postoperative month 7.25. These patients survived for 2–23 months. The geometric mean survival time was 6.83 months, standard deviation of 2.12. There was a statistically significant difference between the two subgoups in the survival time parametres (p = 0.009), thereas, the difference in ascites relapse rates was statistically insignificant (p = 0.12). In the whole study group, in-hospital morbidity was 16.6% and lethality 3.3%.
Conclusions:
HIPEC with/without debulking is an efficient method for controlling, managing or preventing the development of malignant ascites, it extends the mean survival time of the patients (especially when bulking is feasible) with low morbidity and lethality rates of the procedure.
Key words:
ascites – malignant ascites – hyperthermic intraperitoneal peroperative chemotherapy (HIPEC)
Sources
1. Saif, M. W., Siddiqui, I. A., Sohail, M. A. Management of ascites due to gastrointestinal malignancy. Ann. Saudi Med., 2009 Sept-Oct; 29(5): 369–377.
2. Becker, G., Galandi, D., Blum, H. E. Malignant ascites: systematic review and guideline for treatment. Eur. J. Cancer, 2006 Mar; 42(5): 589–972.
3. Smith, E. M., Jayson, G. C. The current and future management of malignant ascites. Clin. Oncol. (R. Coll. Radiol.), 2003 Apr; 15(2): 59–72.
4. Lin, O. Challenges in the interpretation of peritoneal cytologic speciments. Arch. Pathol. Lab. Med., 2009 May; 133 (5): 739–742.
5. Chung, M., Kozuch, P. Treatment of malignant ascites. Curr. Treat. Options Oncol., 2008 Jun; 9(2–3): 215–33. Epub 2008 Sep 6.
6. Hu, L., Hofmann, J., Holash, J., et al. Vascular endothelial growth factor trap combined with Paclitaxel strinkingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin. Cancer Res., 2005;11(19 ) October 1: 6966–6971.
7. Los, G., Smals, O. A., van Vugt, M. J., van der Vlist, M., den Engelse, L., McVie, J. G., Pinedo, H. M. A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity. Cancer Res., 1992 Mar 1; 52(5): 1252–1258.
8. Adam, R. A., Adam, Y. G. Malignant ascites: past, present, and future. J. Am. Coll. Surg., 2004 Jun; 198(6): 999–1011.
9. Rosenshein, N., Blake, D., McIntyre, P. A., Parmley, T., Natarajan, T. K., Dvornicky, J., Nickoloff, E. The effect of volume on the distribution of substances instilled into the peritoneal cavity. Gynecol. Oncol., 1978 Feb; 6(1): 106–110.
10. Loggie, B. W., Fleming, R. A., McQuellon, R. P., Russell, G. B., Geisinger, K. R. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin. Am. Surg., 2000 Jun; 66(6): 561–568.
11. Loggie, B. W., Perini, M., Fleming, R. A., Russell, G. B., Geisinger, K. Treatment and prevention of malignant ascites associated with disseminated intraperitoneal malignancies by aggressive combined-modality therapy. Am. Surg., 1997 Feb; 63(2): 137–143.
12. Loggie, B. W., Fleming, R. A., McQuellon, R. P., Russell, G. B., Geisinger, K. R., Levine, E. A. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am. Surg., 2001 Oct; 67(10): 999–1003.
13. Gilly, F. N., Carry, P. Y., Brachet, A., Sayag, A. C., Panteix, G., Salle, B., Bienvenu, J., Banssillon, V., Burgard, G., Manchon, M., et al. Treatment of malignant peritoneal effusion in digestive and ovarian cancer. Med. Oncol. Tumor Pharmacother., 1992; 9(4): 177–181.
14. Francois, Y., et al. Intraperitoneal chemo-hyperthermia with mitomycin C in cancer of the stomach with peritoneal carcinosis. J. Chir. (paris), 1997; 134 (5–6): 237–242.
15. Garofalo, A., Valle, M., Garcia, J., Sugarbaker, P. H. Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites. Eur. J. Surg. Oncol., 2006 Aug; 32(6): 682–685. Epub 2006 Apr 21.
16. Kusano, H., et al. Continuous hyperthermic peritoneal perfusion (CHPP) for prevention or treatment of peritoneal dissemination. Gan To Kagaku Ryoho, 1993; 20 (11): 1622–1625
17. Verwaal, V. J., et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J. Clin. Oncol, 2003; 21(20): 3737–3743.
18. Valle, M., Speeten, V. M., Garofalo, A. Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy ( HIPEC ) in the management of refractory malignit ascites : A muilti-institutional retrospective analysis in 52 patients. Eur. J. Surg. Oncol., 2008 Feb; 34(2): 154–158.
19. Facchiano, E., Scaringi, S., Kianmanesh, R., et al. Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer. Anticancer Res., 2009 Aug; 29(8): 3353–3359.
Labels
Surgery Orthopaedics Trauma surgeryArticle was published in
Perspectives in Surgery
2010 Issue 4
Most read in this issue
- Malignant Ascites – Optional Management using Hyperthermic Peroperative Chemotherapy (HIPEC)
- Mesenteric Ischemia – Late Diagnosis or Managed Disease?
- Stapler Procedure for Anal Prolapse and Hemorrhoids: Long-term Results
- Rare Tumors of the Gallbladder and Bile Ducts. A Case Review